|
PharmaResearch is a South Korean pharmaceutical and medical device manufacturer established in 2001. The company develops, manufactures, and distributes products based on Polydeoxyribonucleotide (PDRN) and Polynucleotide (PN) technologies derived from salmon DNA. Its business segments include pharmaceuticals, medical devices, and cosmetics. Key products include the skin booster Rejuran, the joint injection Conjuvan, the ophthalmic solution Rejuvenex, and the botulinum toxin Lientox. The company also imports and distributes imported pharmaceuticals. PharmaResearch serves domestic hospitals and clinics as well as international markets in Asia, Europe, and North America. Its subsidiary, PharmaResearch Bio, specializes in botulinum toxin production and export. The company operates GMP-certified manufacturing facilities in Gangneung, South Korea. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Medical Devices | Homepage pharmaresearch.com |
| Sector Healthcare | IR page pharmaresearch.com | |
|
Tags
regenerative medicine, skin boosters, botulinum toxin, ophthalmic solutions, joint injections, cosmetics, pdrn, pn, anti-aging, dermatology, Rejuran, Conjuvan, Rejuvenex, Lientox, Placentex, Zadakxin, Clavil, Rejuviel, Rejuran Cosmetic, PharmaResearch Bio, PharmaResearch Medicaire
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | ₩ 6.263T |
| Market cap (USD) | $ 4.61B |
| P/E | 14.49 |
| PEG | 0.24 |
| P/BV | 8.31 |
| P/S | 10.38 |
| P/OCF | 36.23 |
| P/FCF | 45.42 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 26.9% |
| ROI | 24.0% |
| ROIC | 24.2% |
| Profit margin | 30.8% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | 59.7% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | — |
| Diluting (TTM) | — |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | 53.3% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 536.289B | 350.115B | 261.011B | 194.759B | 154.083B | 108.746B | 83.872B | 64.281B | 54.47B | 45.953B | 37.455B | 24.765B | 17.771B |
| Net profit | 165.121B | 92.043B | 76.551B | 40.577B | 46.689B | 32.774B | 16.667B | 14.408B | 12.956B | 13.909B | 12.878B | 8.838B | 5.662B |
| Free cash flow | 153.435B | 101.707B | 52.883B | 42.19B | 44.652B | -2.393B | 9.687B | -23.394B | 1.803B | 6.783B | 15.673B | -3.864B | 1.708B |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (KRW) | 10.8B | 15B | 15.9B | 20.2B | 22.8B | 27.7B | 32.3B | 31.4B | 38.5B | 44.5B |
| ↳ YoY growth | +84.3% | +38.9% | +5.9% | +27.3% | +13.0% | +21.5% | +16.4% | -2.8% | +22.5% | +15.7% |
| ↳ 5y CAGR | +34.2% | +26.4% | +31.3% | +20.8% | +16.6% | +14.6% | +13.7% | +14.3% | ||
| Other receivables (KRW) | — | 3.05B | — | — | — | — | — | 4.6B | 18.1B | 12.8B |
| Borrowings, current (KRW) | 0.00 | 0.00 | — | — | 15B | 15.8B | 15.6B | 400M | 9.36B | 7.97B |
| Borrowings, non-current (KRW) | 0.00 | 0.00 | 1.83B | 1.22B | 773M | 21.3B | 22.3B | 193M | 1.22B | 434M |
| Bonds payable (KRW) | — | 0.00 | — | — | — | 20.6B | 22.1B | 0.00 | 9.11B | 7.97B |
| Lease liabilities (KRW) | — | — | — | 358M | 1.12B | 2.63B | 2.46B | 958M | 3.54B | 2.05B |
| Cash and deposits (KRW) | 17.6B | 17B | 21.1B | 19.7B | 26.7B | 41.7B | 72.9B | 67.2B | 165B | 176B |
| Intangible assets (KRW) | 4.21B | 3.32B | 45.7B | 43.5B | 39.3B | 42.8B | 37.8B | 32B | 33.4B | 31.5B |
| Net debt (borrowings + leases - cash) (KRW) | -17.6B | -17B | -19.3B | -18.2B | -9.82B | -1.96B | -32.6B | -65.7B | -151B | -165B |
| Cash flow detail | ||||||||||
| Operating cash flow (KRW) | 8.16B | 8.56B | 5.2B | 19.3B | 32.4B | 65.3B | 59.4B | 64.9B | 138B | 183B |
| Purchases of property, plant and equipment (KRW) | -1.38B | -6.75B | -28.6B | -9.59B | -34.8B | -20.6B | -17.2B | -12.1B | -36.4B | -29.7B |
| Purchases of intangible assets (KRW) | -580M | -121M | -838M | -198M | -598M | -3.14B | -544M | -1.13B | -2.31B | -6.05B |
| Dividends paid (cash effect) (KRW) | -1.89B | -2.82B | -2.8B | -2.97B | -2.96B | -5.03B | -6.32B | -7.53B | -10.1B | -11.7B |
| Share buybacks (cash effect) (KRW) | -2.68B | -2.3B | — | -4.99B | — | — | — | — | — | — |
| Interest paid (cash effect) (KRW) | 0.00 | -7.78M | -75.9M | -184M | -117M | -196M | -159M | -494M | -429M | -2.18B |
| Income taxes paid (cash effect) (KRW) | -4.01B | -3.43B | -4.55B | -2.49B | -5.86B | -10.1B | -13.8B | -17B | -19.8B | -39.6B |
| Free cash flow (OCF - PPE - intangibles) (KRW) | 6.2B | 1.68B | -24.2B | 9.49B | -2.99B | 41.5B | 41.6B | 51.7B | 99.4B | 147B |
| Income detail | ||||||||||
| Total comprehensive income (KRW) | 14B | 11.9B | 12B | 15.3B | 32.1B | 46.2B | 39.4B | 78.6B | 90.8B | 168B |
| Comprehensive income to owners (KRW) | 14.1B | 12.4B | 15B | 17.1B | 32.4B | 46.1B | 36.6B | 77.7B | 94B | 165B |
| Provision for credit losses (KRW) | 65M | — | — | — | — | — | — | — | — | — |
| Credit cost ratio (credit losses / average receivables) (%) | 0.8% | — | — | — | — | — | — | — | — | — |
| Reported | Apr 2, 2018 | Aug 14, 2018 | Mar 29, 2019 | Mar 27, 2020 | Mar 18, 2021 | Mar 15, 2024 | Mar 15, 2024 | Mar 19, 2026 | May 21, 2025 | Mar 19, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpDisclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding PharmaResearch
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVEE | 0.13% | 904 | $ 172.855K | Nov 16, 2026 |
| AVXC | 0.05% | 988 | $ 188.917K | Nov 16, 2026 |
| DFSE | 0.03% | 996 | $ 185.283K | Nov 12, 2026 |
| DEHP | 0.03% | 554 | $ 103.059K | Nov 12, 2026 |
| DEXC | 0.02% | 329 | $ 61.203K | Nov 12, 2026 |
| AVEM | 0.02% | 22,522 | $ 4.306M | Nov 16, 2026 |
| DFEM | 0.02% | 9,499 | $ 1.767M | Nov 12, 2026 |
| DFAE | 0.01% | 5,622 | $ 1.046M | Nov 12, 2026 |
| DFAX | 0.01% | 6,461 | $ 1.202M | Nov 12, 2026 |
| AVSE | 0.00% | 43 | $ 8,222.08 | Nov 16, 2026 |

![[이미지] 11일 개최된 대한미용비만재생학회 현장 부스 전경.jpg](https://pharmaresearch.com/smarteditor/upload/202610150938252098720871.jpg)
![[사진] 리쥬란코스메틱 브랜드 파트너 이재(EJAE)와 협업한 웨딩 준비 스킨케어 루틴 콘텐츠.jpg](https://pharmaresearch.com/smarteditor/upload/202610150936361993741481.jpg)
![[이미지] 파마리서치 ‘리쥬란’.jpg](https://pharmaresearch.com/smarteditor/upload/202610150932441272447718.jpg)
![[이미지] 파마리서치, 의료진 전용 에스테틱 플랫폼 ‘더미결’ 오픈.jpg](https://pharmaresearch.com/smarteditor/upload/2026100723223885720194.jpg)
![[이미지] ‘리쥬란 리제너레이션 로드쇼 파리'.jpg](https://pharmaresearch.com/smarteditor/upload/202610020212491441347096.jpg)
![[이미지] 파마리서치 영업마케팅본부장 윤관식 전무(좌), 패스트레인 손승우 대표(우).jpg](https://pharmaresearch.com/smarteditor/upload/20261002021114545824160.jpg)
![[사진] 파마리서치, ‘2026 인적자원개발 우수기관’ 선정.jpg](https://www.pharmaresearch.com/smarteditor/upload/20260922112627406899408.jpg)
![[사진] 파마리서치, 中 화장품 기업 Chicmax와 MOU 체결.jpg](https://www.pharmaresearch.com/smarteditor/upload/202609211020051855864198.jpg)
![[사진] 14일 헝가리 부다페스트 미술관에서 개최된 리쥬란 심포지엄 현장.jpg](https://www.pharmaresearch.com/smarteditor/upload/202609210816581319113121.jpg)
![[사진1] 11일 리야드에서 개최된 리쥬란 론칭 심포지엄 현장.jpg](https://www.pharmaresearch.com/smarteditor/upload/20260921081309640963502.jpg)
![[사진2] 12일 제다에서 개최된 리쥬란 론칭 심포지엄 현장.jpg](https://www.pharmaresearch.com/smarteditor/upload/20260921081318482946881.jpg)